---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-021937"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:40:45.086402+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology Q2 net income $2.1M, down from $9.4M YoY; revenue flat at $51.6M

## Summary
- GAAP net income $2.1M ($0.05/diluted share) vs $9.4M ($0.21) Q2 2022; non-GAAP adj net income $4.6M ($0.10).
- Product revenue from NERLYNX $51.6M, slightly up from $51.3M YoY; royalty revenue fell to $3.0M from $8.2M.
- Net cash from operations positive $3.3M vs -$13.9M Q2 2022; cash & securities $74.4M at June 30.
- FY 2023 guidance: product revenue $205-210M, net income $20-24M; Q3 product revenue guided $51-53M.
- Pipeline milestones: Phase II alisertib in small cell lung cancer H2 2023; FDA meeting Q4 for HR+ HER2- breast cancer.

## SEC filing metadata
- accession: 0001437749-23-021937
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774923021937/0001437749-23-021937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774923021937/pbyi20230731_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-021937
- JSON: https://secwatch.observer/filing/0001437749-23-021937.json
- Plain text: https://secwatch.observer/filing/0001437749-23-021937.txt

## Key facts
- Earnings Releases
  PUMA BIOTECHNOLOGY, INC. reported the second quarter ended June 30, 2023 results: revenue $51.6 million, net income $2.1 million, EPS $0.05 per basic and diluted share.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $51.6 million
  - Net income: $2.1 million
  - EPS: $0.05 per basic and diluted share
  - Result: reported results
  source text: Product revenue, net in the second quarter of 2023 was $51.6 million, an increase from $51.3 million reported for the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774923021937/0001437749-23-021937-index.htm
- Earnings Releases
  PUMA BIOTECHNOLOGY, INC. reported the first six months of 2023 results: revenue $98.3 million, net income $3.5 million, EPS $0.08 per basic share and $0.07 per diluted share.
  - Period: the first six months of 2023
  - Revenue: $98.3 million
  - Net income: $3.5 million
  - EPS: $0.08 per basic share and $0.07 per diluted share
  - Result: reported results
  source text: Product revenue, net in the first six months of 2023 was $98.3 million, compared to $92.0 million in the first six months of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774923021937/0001437749-23-021937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.